Tuesday, March 8, 2022

Adverse Event Reports (4))

Cumulative Analysis of Post-authorization Adverse Event Reports 

fasciitis:

Eosinophilic granulomatosis with polyangitis,

Eosinophilic oesophagitis:

Epidermolysis:

Epilcpsy:

Epilepsy surgery:

Epilepsy with myoclonic-atonic scizures;

 Epileptic aura; 

Epileptic psychosis:

Erythema; 

Erythema induratum; 

Erythema multiforme:

Erythema nodosum,

Evans syndrome:

Exathema subitum,

Expanded disability status scale score decreased:

Expanded disability status scale score increased:

Exposure to communicable disease:

Exposure to SARS-CoV-2:

Eye oedema:

Eye pruritus:

Eye swelling:

Eyelid oedema:

Face ocdema; 

Facial paralysis:

Facial paresis:

Faciobrachial dystonic seizure:

Fat embolism; 

Febrile convulsion:

Febrile infection-related epilepsy syndrome; 

Febrile neutropenia; 

Felty's syndrome:

Femoral artery embolism:

Fibrillary glomerulonephritis,

Fibromyalgia:

Flushing :

Foaming at mouth:

Focal cortical resection:

Focal dyscognitive seizures:

Foetal distress syndrome:

Foetal placental thrombosis; 

Foetor hepaticus:

Foreign body embolism:

Frontal lobe epilepsy:

Fulminant type 1 diabetes mellitus:

Galactose elimination capacity test abnormal:

Galactose elimination capacity test decreased; 

Gamma-glutamyltransferase abnomal; 

Gamma-glutamyltransferase increased:

Gastritis herpes; 

Gastrointestinal amyloidosis;

Gelastic seizure:

Generalised onset non-motor seizure; 

Generalised tonic-clonic seizure:

Genital herpes; 

Genital herpes simplex; 

Genital herpes zoster,

Giant cell arteritis;

 Glomerulonephritis;

 Glomerulonephritis membranoproliferative; 

Glomerulonephritis membranous;:

Glomerulonephritis rapidly progressive:

Glossopharyngeal nerve paralysis

Glucose transporter type 1 deficiency syndrome; 

Glutamate dehydrogenase increased;

 Glycocholic acid increased:

GM2 gangliosidosi

Goodpasture's syndrome; 

Graft thrombosis;

Granulocytopenia;

Granulocytopenia nconatal:

Granulomatosis with polyangitis:

Granulomatous dermatitis:

Barre syndrome:

Haemolytic anacmia;

 Haemophagocytic lymphohistiocytosis:

Haemonhage:

Hae morhagic ascites:Hacmorhagic disorder:Haemorhagic pneumonia:Haemorhagic varicella syndrome:

Haemorhagic vasculitis; Hantavirus pulmonary infection:Hashimoto's encephalopathy:

Hashitoxicosis.

Hemimegalencephaly.

Henoch-Schonlein purpura; 

Henoch- Schonlein purpura nephritis:

Hepaplastin abnomal:

Hepaplastin decreascd:

Heparin-induced thrombocytopenia:

Hepatic amyloidosis:

Hepatic artery embolism,

Hepatic artery flow deereased:

Hepatic artery thrombosis:

Hepatic enzyme abnormal:

Hepatic enzyme decreased; 

Hepatic enzyme increased

Hepatic fibrosis marker abnormal:

Hepatic fibrosis marker increased:

Hepatic function abnormal:

Hepatic hydrothorax:

Hepatic hypertrophy:

Hepatic hypoperfusion: 

Hepatic lymphocytic infiltration:

Hepatic mass:Hepatic pain:

Hepatic scquestration:

Hepatic vascular resistance increased:

Hepatic vascular thrombosis:

Hepatic vein embolism; 

Hepatic vein thrombosis:

Hepatic venous pressure gradient abnormal:

Hepatic venous pressure gradient increased;

 Hepatitis:

Hepatobiliary scan abnormal:

Hepatome galy:

Hepatosplenomegaly,

Hereditary angioedema with Cl esterase inhibitor deficiency:

Herpes dermatitis:

Herpes gestationis:

Herpes oesophagitis:

Herpes ophthalmic:

Herpes pharyngitis:

Herpes sepsis:

Herpes simplex:

Herpes simplex cervicitis:

Herpes simplex colitis:

Herpes simplex encephalitis:

Herpes simplex gastritis:

Hepes simplex hepatitis:

Herpes simplex meningitis:

Herpes simplex meningoencephalitis

Herpes simplex meningomyelitis:

Herpes simplex necrotising retinopathy:

Herpes simplex oesophagitis:

Herpes simplex otitis externa:Herpes simplex pharyngitis:

Herpes simplex pneumonia :

Herpes simplex reactivation:

Herpes simplex sepsis:

Herpes simplex viraemia:

Herpes simplex vinus conjunctivitis neonatal;:

Herpes simplex visceral; 

Herpes vinus matter heterotopia:

Guanase increased; 

Guillain- 

CONFIDENTIAL 

Page 4  

FDA-CBER-2021-5683-0000086 Pag

No comments:

Post a Comment